secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001558370-22-012871
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros reports Q2 2022 net loss $30.9M; narsoplimab FDA dispute decision expected August
--------------------------------------------------------------------------------

- Royalties of $17.2M on OMIDRIA sales of $34.5M, a new all-time high.
- Net loss $30.9M ($0.49/share) vs $28.6M ($0.46/share) in Q2 2021.
- Cash and short-term investments $122.6M as of June 30, down $19.7M from Q1.
- Submitted Formal Dispute Resolution to FDA for narsoplimab in TA-TMA; decision expected in August 2022.
- OMS906 received orphan drug designation for PNH; Phase 1b trials expanding to treatment-naïve and C3G patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000155837022012871/0001558370-22-012871-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000155837022012871/omer-20220809x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-012871

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer